Cover Image
市場調查報告書

PharmaPoint:帕金森氏症 - 美國的醫藥品的預測與市場分析

PharmaPoint: Parkinson's Disease - US Drug Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 301424
出版日期 內容資訊 英文 209 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:帕金森氏症 - 美國的醫藥品的預測與市場分析 PharmaPoint: Parkinson's Disease - US Drug Forecast and Market Analysis to 2022
出版日期: 2014年03月31日 內容資訊: 英文 209 Pages
簡介

帕金森氏症的症狀是以動作緩慢、肌肉僵硬、震顫和姿勢不穩為特徵的一個漸進式疾病。是發病率第二高的神經退化性疾病,無論何種年齡層都有受到影響的可能性,得病率隨著年齡增長而上升,高齡者更是常見。雖然多巴胺療法對動作遲緩相當有效,但仍留有許多未滿足需求。

本報告提供美國帕金森氏症治療藥市場相關的調查分析,提供疾病的概要與指南,競爭情形,主要藥物的詳細資訊(產品說明,安全性,有效性),彙整SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
    • 預測
    • QOL
  • 症狀

第4章 疾病的管理

  • 概要
  • 治療概要
  • 帕金森氏症的評估規模
  • 帕金森氏症的診斷和治療:各國

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介 - 左旋多巴混合製劑
  • 產品簡介 - COMT抑制劑
  • 多巴胺受體激動劑
  • 產品簡介 - MAO-B抑制劑
  • 產品簡介 - AdenosineA2A受體拮抗劑
  • 產品簡介 - 其他治療方法

第6章 機會及未滿足需求

  • 概要
  • 運動併發症的治療
  • 非運動併發症的治療
  • 神經保護/疾病修飾劑
  • 改善藥物配方
  • 可靠性高的生物標記
  • 改善臨床試驗的設計

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
    • Safinamide
    • Tozadenant
    • CVT-301
    • Rytary/IPX066
    • Opicapone
    • Mavoglurant/AFQ056
    • CD/LD-GR
    • 其他後期開發中產品

第8章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Merck
    • Roche
    • AbbVie
    • UCB
    • GlaxoSmithKline
    • Novartis
    • Orion
    • Newron
    • Civitas
    • Impax
    • Lundbeck

第9章 市場預測

  • 美國

第10章 附錄

圖表

目錄
Product Code: GDHC235CFR

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

This market is expected to grow faster than any other market, including the 5EU, due in part to the introduction of two brands already in use in the 5EU, Neupro and Duodopa, launched in the US at the beginning of the forecast in 2012 and 2014, respectively. Other factors responsible for growth in this market are an aging population that contributes to an increased prevalence of Parkinson's disease in the US and the launch of six new pipeline agents (in addition to Duodopa and Neupro).

Scope

  • Overview of Parkinson's Disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in US including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in US from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the US Parkinson's Disease market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Parkinson's Disease
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in US

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Overview
    • 4.1.1. Diagnosis - The UK Brain Bank Criteria
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
  • 4.2. Treatment Synopsis
    • 4.2.1. Dopaminergic Therapy Classes
    • 4.2.2. Treatment of Parkinson's disease by Stage
    • 4.2.3. Other Treatment Options
  • 4.3. Parkinson's Disease Assessment Scales
    • 4.3.1. Unified Parkinson's Disease Rating Scale (UPDRS)
    • 4.3.2. Hoehn and Yahr Clinical Staging
    • 4.3.3. Other Clinical Assessments
  • 4.4. Diagnosis and Treatment of Parkinson's Disease by Country
    • 4.4.1. US

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Levodopa Combination Therapy
    • 5.3.1. Sinemet (carbidopa/levodopa)
    • 5.3.2. Duodopa (carbidopa/levodopa intestinal gel)
  • 5.4. Product Profiles - COMT Inhibitors
    • 5.4.1. Stalevo/Comtan (entacapone)
  • 5.5. Dopamine Agonists
    • 5.5.1. Neupro (rotigotine transdermal patch)
    • 5.5.2. Requip/Requip XL (ropinirole)
    • 5.5.3. Apokyn (apomorphine)
  • 5.6. Product Profiles - MAO-B Inhibitors
    • 5.6.1. Azilect (rasagiline)
  • 5.7. Product Profiles - Adenosine 2A Inhibitor
    • 5.7.1. Nouriast (istradefylline)
  • 5.8. Product Profiles - Other Therapies

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Treatment of Motor Complications - Dyskinesias and OFF Episodes
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Treatment of Non-Motor Symptoms and Dementia
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Neuroprotective/Disease-Modifying Agents
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Improved Drug Formulations
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Identification of Reliable Biomarkers
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Improved Clinical Trial Design
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Safinamide
    • 7.2.2. Tozadenant
    • 7.2.3. CVT-301
    • 7.2.4. Rytary/IPX066
    • 7.2.5. Opicapone
    • 7.2.6. Mavoglurant/AFQ056
    • 7.2.7. CD/LD-GR
    • 7.2.8. Other Late-Stage Pipeline Products

8. Current and Future Players

  • 8.1. Overview
  • 8.2. Trends in Corporate Strategy
  • 8.3. Company Profiles
    • 8.3.1. Merck
    • 8.3.2. Roche
    • 8.3.3. AbbVie
    • 8.3.4. UCB
    • 8.3.5. GlaxoSmithKline
    • 8.3.6. Novartis
    • 8.3.7. Orion
    • 8.3.8. Newron
    • 8.3.9. Civitas
    • 8.3.10. Impax
    • 8.3.11. Lundbeck

9. Market Outlook

  • 9.1. US
    • 9.1.1. Forecast
    • 9.1.2. Key Events
    • 9.1.3. Drivers and Barriers - Global Issues
    • 9.1.4. Drivers and Barriers

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Diagnosed Parkinson's Disease Patients
    • 10.4.2. Percent Drug-Treated Patients
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch and Patent Expiry Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Compliance Assumptions
    • 10.4.7. Individual Drug Assumptions
    • 10.4.8. Generic Erosion
    • 10.4.9. Pricing of Pipeline Agents
  • 10.5. Physicians and Specialists Included in this Study
  • 10.6. About the Authors
    • 10.6.1. Author
    • 10.6.2. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Parkinson's Disease
  • Table 2: UK Brain Bank Diagnostic Criteria
  • Table 3: Diagnosis and Treatment Guidelines for Parkinson's Disease
  • Table 4: Most Prescribed Drugs for Parkinson's Disease by Class in the Global Markets, 2014
  • Table 5: Dopaminergic Therapy in Parkinson's Disease
  • Table 6: UPDRS Clinical Assessment of Disease Severity
  • Table 7: Parkinson's Disease Assessment Scales Used in Clinical Trials
  • Table 8: Parkinson's Disease, Country Profile - US
  • Table 9: Treatment of Motor Symptoms in Parkinson's Disease
  • Table 10: Leading Treatments for Parkinson's Disease, 2014
  • Table 11: Product Profile - Sinemet
  • Table 12: Sinemet SWOT Analysis, 2014
  • Table 13: Product Profile - Duodopa
  • Table 14: Duodopa SWOT Analysis, 2014
  • Table 15: Product Profile - Stalevo
  • Table 16: Product Profile - Comtan
  • Table 17: Stalevo/Comtan SWOT Analysis, 2014
  • Table 18: Product Profile - Neupro
  • Table 19: Neupro SWOT Analysis, 2014
  • Table 20: Product Profile - Requip/Requip XL
  • Table 21: Requip/Requip XL SWOT Analysis, 2014
  • Table 22: Product Profile - Apokyn
  • Table 23: Apokyn SWOT Analysis, 2014
  • Table 24: Product Profile - Azilect
  • Table 25: Azilect SWOT Analysis, 2014
  • Table 26: Product Profile - Nouriast
  • Table 27: Nouriast SWOT Analysis, 2014
  • Table 28: Summary of Alternative Parkinson's Disease Therapies
  • Table 29: Unmet Need and Opportunity in Parkinson's Disease
  • Table 30: Dyskinesia Pipeline, 2014
  • Table 31: Dementia Pipeline, 2014
  • Table 32: Parkinson's Disease-Modifying Therapeutics Pipeline, 2014
  • Table 33: Product Profile - Safinamide
  • Table 34: Summary of Relevant Clinical Trials for Safinamide
  • Table 35: Safinamide SWOT Analysis, 2014
  • Table 36: Product Profile - Tozadenant
  • Table 37: Tozadenant SWOT Analysis, 2014
  • Table 38: Product Profile - CVT-301
  • Table 39: CVT-301 SWOT Analysis, 2014
  • Table 40: Product Profile - Rytary
  • Table 41: Rytary SWOT Analysis, 2014
  • Table 42: Product Profile - Opicapone
  • Table 43: Opicapone SWOT Analysis, 2014
  • Table 44: Product Profile - Mavoglurant
  • Table 45: Mavoglurant SWOT Analysis, 2014
  • Table 46: Product Profile - CD/LD-GR
  • Table 47: Summary of Relevant Clinical Trials for CD/LD-GR
  • Table 48: CD/LD-GR SWOT Analysis, 2014
  • Table 49: Late-Stage Pipeline, 2013
  • Table 50: Key Companies in the Parkinson's Market, 2014
  • Table 51: Merck's Parkinson's Disease Portfolio Assessment, 2014
  • Table 52: Merck's PD SWOT Analysis, 2014
  • Table 53: Roche's Parkinson's Disease Portfolio Assessment, 2014
  • Table 54: Roche's PD SWOT Analysis, 2014
  • Table 55: AbbVie's Parkinson's Disease Portfolio Assessment, 2014
  • Table 56: AbbVie's PD SWOT Analysis, 2014
  • Table 57: UCB's Parkinson's Disease Portfolio Assessment, 2014
  • Table 58: UCB's PD SWOT Analysis, 2014
  • Table 59: GSK's Parkinson's Disease Portfolio Assessment, 2014
  • Table 60: GSK's PD SWOT Analysis, 2014
  • Table 61: Novartis' Parkinson's Disease Portfolio Assessment, 2014
  • Table 62: Novartis' PD SWOT Analysis, 2014
  • Table 63: Orion's Parkinson's Disease Portfolio Assessment, 2014
  • Table 64: Orion's PD SWOT Analysis, 2014
  • Table 65: Newron's Parkinson's Disease Portfolio Assessment, 2014
  • Table 66: Newron's PD SWOT Analysis, 2014
  • Table 67: Civitas' Parkinson's Disease Portfolio Assessment, 2014
  • Table 68: Civitas' PD SWOT Analysis, 2014
  • Table 69: Impax's Parkinson's Disease Portfolio Assessment, 2014
  • Table 70: Impax's PD SWOT Analysis, 2014
  • Table 71: Lundbeck's Disease/Therapy Portfolio Assessment, 2014
  • Table 72: Lundbeck's SWOT Analysis, 2014
  • Table 73: Sales Forecasts ($m) for Parkinson's Disease in the US, 2012-2022
  • Table 74: Key Events Impacting Sales for Parkinson's Disease in the US, 2012-2022
  • Table 75: Parkinson's Disease Market - Drivers and Barriers, 2012-2022
  • Table 76: Parkinson's Disease Market in the US - Drivers and Barriers, 2012-2022
  • Table 77: Key Launch Dates
  • Table 78: Key Patent Expiries

List of Figures

  • Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes
  • Figure 2: Overview - Treatment of Motor Symptoms of Parkinson's Disease
  • Figure 3: Pharmacokinetics of Levodopa
  • Figure 4: Parkinson's Disease - Phase II-III Pipeline, Segmented by Indication, 2014
  • Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in Parkinson's Disease, 2012-2022
  • Figure 6: Company Portfolio Gap Analysis in Parkinson's Motor Symptoms, 2012-2022
  • Figure 7: Sales for Parkinson's Disease in the US by Drug Class, 2012-2022
Back to Top